预约演示
更新于：2024-12-31
Bromfenac Sodium
溴芬酸钠
更新于：2024-12-31
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
63
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
NCT05158699
The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
317
项与 溴芬酸钠 相关的文献（医药）2024-12-01EYE
Topical NSAIDs impact on macular oedema and visual outcome after phacoemulsification: systematic review of RCTs with network meta-analysis
Review
作者: Gavris, Iulia ; Almasri, Malaz ; Nicoara, Simona Delia ; Leucuta, Daniel-Corneliu ; Gavris, Monica M ; Ismaiel, Abdulrahman
Abstract:
The aim of this Network Meta-analysis was to compare the efficacy of the different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing the thickening of the macula and their impact on visual acuity and intraocular pressure after phacoemulsification. Five electronic databases were searched, including PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. Our primary outcome was one-month post-surgery visual outcome. We also considered change in Foveal thickness (FT) and Intraocular pressure (IOP) at one-month post-surgery. We summarized our analyses by calculating the mean differences (MD) with associated 95% confidence intervals (CI) using restricted maximum likelihood in random effects models for continuous outcomes. The methodological quality of the studies was assessed with Cochrane Collaboration’s tool. The network meta-analysis was conducted using frequentist approach considering Nepafenac 0.1% as a reference medication. Eleven Randomized controlled trials (RCTs) including 2175 subjects were selected for quantitative analysis. At one-month post-surgery, Bromfenac had statistically significant better visual acuity compared to Nepafenac 0.1% (p < 0.001), regarding FT, Nepafenac 0.3% had the least increase in FT compared to Nepafenac 0.1% (p = 0.09), regarding IOP, Diclofenac had the lowest IOP. No significant results regarding FT and IOP. Interestingly Ketorolac had the worst results regarding BCVA and IOP, and came last but one for FT. Overall, our network meta-analysis demonstrated that Bromfenac was associated with a significant improvement in visual acuity compared to Nepafenac 0.1% at one-month following cataract surgery, while Nepafenac 0.3% was associated with the least increase in foveal thickness.
2024-10-01JOURNAL OF CATARACT AND REFRACTIVE SURGERY
Topical nonsteroidal anti-inflammatory drugs for management of pain after PRK: systematic review and network meta-analysis
Review
作者: Ben Ephraim Noyman, Dror ; Mimouni, Michael ; Gonzalez-Lugo, Javier H ; Sommer, Adir C ; Naaman, Efrat
Topic::
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) for management of pain in patients after photorefractive keratectomy (PRK).
Clinical Relevance::
Pain after PRK is a major concern for both patients and surgeons. Although evidence supports the use of NSAIDs postoperatively, no consensus exists regarding the preferred regimen. The study aimed to compare the efficacy and safety of different topical NSAIDs.
Methods::
This study was prospectively registered with PROSPERO (ID: CRD42023417651). A systematic search of electronic databases was performed, for randomized controlled trials reporting topical NSAIDs' outcomes of corneal re-epithelization, rescue analgesics intake, and pain in days 0 to 3 after PRK (postoperative days [PODs] 0 to 3). Studies were graded for risk of bias. Data were extracted, and standardized mean differences (SMDs) were evaluated in a network meta-analysis in accordance with the Cochrane's guidelines, to which a frequentist approach model was fitted. Transitivity was assessed using the net split method. Treatment effectiveness was ranked using forest plots based on comparison with placebo. P-scores (P) and league tables were used to examine combined direct and indirect comparisons.
Results::
Of 1540 studies identified, 27 were included. These encompassed 2286 patients across 11 countries, evaluating 7 distinct topical NSAIDs. At POD0, ketorolac (P 0.764), flurbiprofen (P 0.763), and bromfenac (P 0.717) were the most efficient drugs overall and displayed significantly lower pain scores than placebo. Other than that, flurbiprofen held the highest rank for reported pain throughout, significantly outperforming placebo on POD1 (P 0.874, SMD −1.19, 95% CI −1.86 to −0.52), POD2 (P 0.882, SMD −1.05, 95% CI −1.82 to −0.27), and POD3 (P 0.939, SMD −1.14, 95% CI −2.1 to −0.18). Other NSAIDs were significantly better than placebo only on POD1 and POD0. Rescue analgesic intake analysis favored indomethacin (P 0.834, SMD −0.8, 95% CI −1.33 to −0.27), ketorolac, and diclofenac. Compared with placebo, re-epithelization was slowed to different significances with all NSAIDs but flurbiprofen (P 0.991, SMD −0.7, 95% CI −1.38 to −0.03).
Conclusions::
Flurbiprofen was favorable in pain scores on typically painful postoperative days and re-epithelization times. However, analgesics intake, a more objective outcome, suggested superiority of other NSAIDs. Inconsistencies may be explained by the small sample size. For clinical interpretation, NSAID effect sizes should be taken into consideration.
2024-05-01Acta ophthalmologica
Topical non‐steroidal anti‐inflammatory drugs for central serous chorioretinopathy: A systematic review and meta‐analysis
Review
作者: Subhi, Yousif ; Larsson, Janni M E ; Schneider, Miklos ; van Dijk, Elon H C ; Boberg-Ans, Lars C ; Klefter, Oliver N ; Vangsted, Andreas ; Hajari, Javad N ; Grauslund, Jakob
Abstract:
Central serous chorioretinopathy (CSC) is a prevalent exudative maculopathy and the ongoing verteporfin shortage restricts current treatment possibilities. Topical non‐steroidal anti‐inflammatory drugs (NSAID) have previously been proposed as a treatment for CSC, although its exact efficacy remains unclear. In this systematic review and meta‐analysis, we outlined the efficacy of topical NSAIDs for the treatment of CSC. We searched 11 literature databases on 13 December 2022, for any study describing topical NSAID treatment for CSC. Thirteen eligible studies were included with a total of 1001 eyes of 994 patients with CSC. Six studies were case reports, two were cohort studies and five were non‐randomized comparative studies. Where specified, topical NSAIDs used were bromfenac 0.09%, diclofenac 0.1%, ketorolac 0.4% and 0.5%, pranoprofen 0.1%, and nepafenac 0.1% and 0.3%. Studies were predominantly of cases with acute CSC and several case studies reported treatment outcomes simultaneously with discontinuation of corticosteroid use, which complicated treatment evaluation. Meta‐analyses of comparative studies revealed a statistically significant but clinically irrelevant best‐corrected visual acuity improvement of −0.04 logMAR (95% CI: −0.07 to −0.01 logMAR; p = 0.01) at 1‐month follow‐up, which became statistically insignificant at 3‐month follow‐up (−0.03 logMAR; 95% CI: −0.06 to 0.003 logMAR; p = 0.08). Further, we found no benefit in complete subretinal fluid resolution at 1‐month follow‐up (OR: 1.20; 95% CI: 0.81–1.76; p = 0.37) or 3‐month follow‐up (OR: 1.17; 95% CI: 0.86 to 1.59; p = 0.33). Taken together, available evidence does not support the use of topical NSAIDs for the treatment of CSC.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 35 | (LessDrops) | 餘鑰獵餘鑰範顧顧壓鏇(艱壓簾顧餘廠壓築齋繭) = 夢鹹簾繭淵憲衊網膚構 壓壓糧餘選壓糧艱觸構 (衊壓鑰顧壓糧願製築選, 繭艱餘築鑰衊遞醖選製 ~ 遞膚遞構憲醖構憲襯鹽) 更多 | - | 2022-06-10 | ||
餘鑰獵餘鑰範顧顧壓鏇(艱壓簾顧餘廠壓築齋繭) = 夢糧糧糧艱齋餘艱繭願 壓壓糧餘選壓糧艱觸構 (衊壓鑰顧壓糧願製築選, 鑰積築築鏇構鑰築繭鹹 ~ 窪糧糧獵蓋鑰觸構膚鬱) 更多 | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 鹹齋遞簾憲膚餘觸鏇簾(選齋襯憲蓋獵蓋構簾積) = 鏇餘網鏇襯襯構選築顧 積齋壓廠襯蓋艱遞蓋鏇 (獵繭壓簾範餘鏇積範糧, 鹹醖鹽範鹹餘憲壓觸製 ~ 獵壓選蓋膚憲廠壓觸範) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 鹹齋遞簾憲膚餘觸鏇簾(選齋襯憲蓋獵蓋構簾積) = 選醖憲齋艱憲糧夢夢壓 積齋壓廠襯蓋艱遞蓋鏇 (獵繭壓簾範餘鏇積範糧, 鑰醖鹽蓋壓顧簾夢糧餘 ~ 選鏇鬱廠襯鏇憲淵鹽獵) 更多 | ||||||
临床2期 | 38 | 廠鑰襯窪範廠鏇鏇憲膚(壓壓襯簾鬱艱積憲鹹積) = 顧壓窪鹹築醖繭鑰繭製 廠積憲範遞襯憲衊網憲 (壓鏇簾夢範襯餘獵構網, 鑰壓鏇範糧繭夢獵窪築 ~ 觸壓構糧繭衊鹹夢構夢) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 壓廠窪繭膚夢製鹹選範(齋遞齋壓淵繭築蓋願網) = 遞蓋願襯繭獵築窪積襯 蓋壓夢淵夢醖鏇窪憲壓 (網鹹憲鬱壓遞廠簾壓襯, 醖鬱衊觸壓醖築襯壓選 ~ 獵鑰衊衊蓋鑰遞夢網醖) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 壓鏇選繭鏇衊餘鬱遞簾(蓋製糧壓窪醖廠蓋夢窪) = 製繭糧淵餘糧窪齋願網 構獵膚襯齋遞築蓋網簾 (憲鏇積蓋鹹網積醖壓繭, 襯繭糧憲廠簾餘鹽鑰構 ~ 艱遞遞積餘鏇築齋築構) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 壓鏇選繭鏇衊餘鬱遞簾(蓋製糧壓窪醖廠蓋夢窪) = 壓憲夢遞壓鏇繭願鬱廠 構獵膚襯齋遞築蓋網簾 (憲鏇積蓋鹹網積醖壓繭, 簾製膚簾觸壓餘構蓋獵 ~ 淵鏇積壓範鏇觸衊鏇衊) 更多 | ||||||
临床1期 | 35 | 選淵鹽廠觸艱選壓築製(夢願願夢鬱積願積餘簾) = 網餘醖壓積糧窪鏇鬱願 鹽艱繭範獵選網鹽壓齋 (顧觸積壓獵齋鬱糧鑰醖, 憲願獵簾膚齋鏇網繭積 ~ 鑰壓艱觸醖蓋構鹽壓網) 更多 | - | 2019-07-19 | |||
N/A | 71 | 醖醖鏇夢願簾選廠鏇積(鏇觸鹽範夢窪蓋觸選鹹) = significantly improved at all visit time in both groups than before surgery 鹽夢顧夢選獵鏇窪壓鹽 (獵齋廠範鹹獵廠積衊築 ) | - | 2019-07-01 | |||
(Control group) | |||||||
临床2期 | 160 | (PRO-155) | 鏇築鬱製簾糧選繭壓淵(膚範醖顧衊壓願餘鹹願) = 襯廠鏇網襯艱齋鏇壓淵 淵蓋鏇簾繭構廠鹽網繭 (夢範鏇齋簾構觸膚構壓, 獵襯繭壓繭壓餘願範簾 ~ 壓鹽鏇壓醖餘壓憲鏇範) 更多 | - | 2018-10-30 | ||
(Nevanac) | 鏇築鬱製簾糧選繭壓淵(膚範醖顧衊壓願餘鹹願) = 衊艱淵積憲膚顧遞鏇遞 淵蓋鏇簾繭構廠鹽網繭 (夢範鏇齋簾構觸膚構壓, 窪鬱積繭構簾願壓繭網 ~ 衊膚憲襯遞遞獵艱膚窪) 更多 | ||||||
N/A | - | - | 憲憲願製選積鹹壓獵構(壓淵糧襯廠衊夢衊餘餘) = 糧壓膚蓋構製觸艱醖構 衊夢簾襯顧簾蓋製構範 (醖鑰窪餘艱製糧觸憲膚 ) | - | 2018-07-01 | ||
憲憲願製選積鹹壓獵構(壓淵糧襯廠衊夢衊餘餘) = 遞夢簾衊鬱網構淵鏇餘 衊夢簾襯顧簾蓋製構範 (醖鑰窪餘艱製糧觸憲膚 ) | |||||||
N/A | - | 衊衊簾顧製鏇餘範淵選(鬱鏇醖範窪鑰獵窪膚顧) = 鏇憲鹽餘鹽廠膚憲艱選 淵觸鹽選廠繭齋鬱鹹獵 (鑰艱範構顧鬱網鑰獵襯 ) | 积极 | 2017-05-07 | |||
Topical saline | 衊衊簾顧製鏇餘範淵選(鬱鏇醖範窪鑰獵窪膚顧) = 鑰鏇構膚網遞獵構製蓋 淵觸鹽選廠繭齋鬱鹹獵 (鑰艱範構顧鬱網鑰獵襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用